Sunday, June 06, 2021

Immunotherapy drug delays recurrence in kidney cancer patients


News Release 3-Jun-2021
Dana-Farber Cancer Institute


Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.


No comments:

Post a Comment